Poststroke Hypertonicity: Upper Limb Assessment and Treatment

REFERENCES

• Broeks JG, Lankhorst GJ, Rumping K, Prevo AJ. The long-term outcome of arm function after stroke: results of a follow-up study. Disabil Rehabil. 1999;21:357–364.
   PubMed Web of Science ®Google Scholar
• Sommerfeld DK, Eek EU, Svensson AK, Holmqvist LW, von Arbin MH. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke. 2004;35:134–139.
   PubMed Web of Science ®Google Scholar
• Welmer AK, von Arbin M, Widen Holmqvist L, Sommerfeld DK. Spasticity and its association with functioning and health-related quality of life 18 months after stroke. Cerebrovasc Dis. 2006;21:247–253.
   PubMed Web of Science ®Google Scholar
• Twitchell TE. The restoration of motor function following hemiplegia in man. Brain. 1951;74: 443–480.
   PubMed Web of Science ®Google Scholar
• Weimer AK, Holmqvist LW, Sommerfeld DK. Hemiplegic limb synergies in stroke patients. Am J Phys Med Rehabil. 2006;85:112–119.
   PubMed Web of Science ®Google Scholar
• Mirbagheri MM, Tsao C, Rymer WZ. Association of abnormal neuromuscular properties with impaired voluntary movement. Proceedings of the International Conference of Neural Control of Movement; Spain; 2004.
   Google Scholar
• Tsao C, Mirbagheri MM. Upper limb impairments associated with spasticity in neurological disorders. J NeuroEng Rehabil. 2007;4.
   PubMedGoogle Scholar
• Voerman GE, Fleuren JF, Kallenberg LA, Rietman IS, Snoek GJ, Hermens Hi. Patient ratings of spasticity during daily activities are only marginally associated with long-term surface electromyography. I Neurol Neurosurg Psychiatry. 2009;80:175–181.
   PubMed Web of Science ®Google Scholar
• Wood DE, Burridge JH, van Wijck FM, et al. Biomechanical approaches applied to the lower and upper limb for the measurement of spasticity: a systematic review of the literature. Disabil Rehabil. 2005;27:19–32.
   PubMed Web of Science ®Google Scholar
• Burridge JH, Wood DE, Hermens Hi, et al. Theoretical and methodological considerations in the measurement of spasticity. Disabil Rehabil. 2005;27:69–80.
   PubMed Web of Science ®Google Scholar
• Eke-Okoro ST, Gregoric M, Larsson LE. Alterations in gait resulting from deliberate changes of arm-swing amplitude and phase. Clin Biomech. 1997;12:516–521.
   PubMed Web of Science ®Google Scholar
• Esquenazi A, Mayer N, Garreta R. Influence of botulinum toxin type A treatment of elbow flexor spasticity on hemiparetic gait. Am J Phys Med Rehabil. 2008;87:305-310; quiz 11,29.
   PubMed Web of Science ®Google Scholar
• Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67:206–207.
   PubMed Web of Science ®Google Scholar
• Brashear A, Zafonte R, Corcoran M, et al. Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil. 2002;83:1349–1354.
   PubMed Web of Science ®Google Scholar
• Fleuren JF, Voerman GE, Erren-Wolters CV, et al. Stop using the Ashworth Scale for the assessment of spasticity. I Neurol Neurosurg Psychiatry. 2009;81:46–52.
   PubMed Web of Science ®Google Scholar
• Boyd RN, Graham HK. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol. 1999;6:523–35.
   Google Scholar
• Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med. 1989;320:1517–1521.
   PubMed Web of Science ®Google Scholar
• Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain. 1983;16:87–101.
   PubMed Web of Science ®Google Scholar
• Wissel J, Muller J, Dressnandt J, et al. Management of spasticity associated pain with botulinum toxin A. I Pain Symptom Manage. 2000;20:44–49.
   PubMed Web of Science ®Google Scholar
• Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S. The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance. Scand Rehabil Med. 1975;7:13–31.
   PubMedGoogle Scholar
• Rabadi MH, Rabadi FM. Comparison of the action research arm test and the Fugl-Meyer assessment as measures of upper-extremity motor weakness after stroke. Arch Phys Med Rehabil. 2006;87:962–966.
   PubMed Web of Science ®Google Scholar
• Uniform Data System for Medical Rehabilitation. The FlMware User Guide and Self-Guided Training Manual, Version 5.20. Buffalo: UDSmR; 1999.
   Google Scholar
• Williams BK, Galea MP, Winter AT. What is the functional outcome for the upper limb after stroke? Aust Physiother. 2001;47:19–27.
   Google Scholar
• Carr JFI, Shepherd RB, Nordholm L, Lynne D. Investigation of a new motor assessment scale for stroke patients. Phys Ther. 1985;65:175–180.
   PubMed Web of Science ®Google Scholar
• Poole IL, Whitney SL. Motor assessment scale for stroke patients: concurrent validity and interrater reliability. Arch Phys Med Rehabil. 1988;69:195–197.
   PubMed Web of Science ®Google Scholar
• Stroes-Gascoyne S, Pedersen K, Haveman SA, et al. Occurrence and identification of microorganisms in compacted clay-based buffer material designed for use in a nuclear fuel waste disposal vault. Can I Microbiol. 1997;43:1133–1146.
   PubMed Web of Science ®Google Scholar
• Li S, Kamper DG, Rymer WZ. Effects of changing wrist positions on finger flexor hypertonia in stroke survivors. Muscle Nerve. 2006;33:183–190.
   PubMed Web of Science ®Google Scholar
• Kamper DG, McKenna-Cole AN, Kahn LE, Reinkensmeyer DJ. Alterations in reaching after stroke and their relation to movement direction and impairment severity. Arch Phys Med Rehabil. 2002;83:702–707.
   PubMed Web of Science ®Google Scholar
• Cocchiarella A, Downey J, Darling R. Evaluation of the effect of diazepam on spasticity. Arch Phys Med Rehabil. 1967;48:393–396.
   PubMedGoogle Scholar
• Gelber DA, Good DC, Dromerick A, Sergay S, Richardson M. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke. 2001;32:1841–1846.
   PubMed Web of Science ®Google Scholar
• Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke. 2001;32:2099–2109.
   PubMed Web of Science ®Google Scholar
• Gruenthal M, Mueller M, Olson WL, Priebe MM, Sherwood AM, Olson WH. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord. 1997;35:686–689.
   PubMed Web of Science ®Google Scholar
• Steinberg FU, Ferguson KL. Effect of dantrolene sodium on spasticity associated with hemiplegia. Am Geriatr Soc. 1975;23:70–73.
   PubMed Web of Science ®Google Scholar
• Katrak PH, Cole AM, Poulos CJ, McCauley JC. Objective assessment of spasticity, strength, and function with early exhibition of dantrolene sodium after cerebrovascular accident: a randomized double-blind study. Arch Phys Med Rehabil. 1992;73:4–9.
   PubMed Web of Science ®Google Scholar
• Francisco GE, Hu MM, Boake C, Ivanhoe CB. Efficacy of early use of intrathecal baclofen therapy for treating spastic hypertonia due to acquired brain injury. Brain Inj. 2005;19:359–364.
   PubMed Web of Science ®Google Scholar
• Concalves J, Garcia-March G, Sanchez-Ledesma MJ, Onzain I, Broseta J. Management of intractable spasticity of supraspinal origin by chronic cervical intrathecal infusion of baclofen. Stereotact Funct Neurosurg. 1994;62:108–112.
   PubMedGoogle Scholar
• McCall TD, MacDonald JD. Cervical catheter tip placement for intrathecal baclofen administration. Neurosurgery. 2006;59:634-640; discussion -634.
   PubMed Web of Science ®Google Scholar
• Azouvi P, Mane M, Thiebaut113, Denys P, Remy-Neris 0, Bussel B. Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up. Arch Phys Med Rehabil. 1996;77:35–39.
   PubMed Web of Science ®Google Scholar
• Koman LA, Mooney IF 3rd, Smith BP. Neuromuscular blockade in the management of cerebral palsy. Child Neurol. 1996;11 (Suppl 1):523–28.
   Google Scholar
• Hisey M, Keenan M. Orthopaedic management of upper extremity dysfunction following stroke or brain injury. In: Green DP, Hotchkiss RN, Pederson WC, eds. Operative Hand Surgery. New York: Churshill Livingstone; 1998:287–324.
   Google Scholar
• Keenan MA, Fuller DA, Whyte J, Mayer N, Esquenazi A., Fidler-Sheppard R.. The influence of dynamic polyelectromyography in formulating a surgical plan in treatment of spastic elbow flexion deformity. Arch Phys Med Rehabil. 2003;84:291–296.
   PubMed Web of Science ®Google Scholar
• Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1707–1714.
   PubMed Web of Science ®Google Scholar
• Esquenazi A, Novak I, Sheean G, Singer BJ, Ward AB. International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments-introduction. Eur Neurol. 2010;17(Suppl 2):1–8.
   Google Scholar
• Shaw L, Rodgers H, Price C, et al. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technol Assess. 2010;14:1-113, iii-iv.
   PubMed Web of Science ®Google Scholar
• Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl Med. 2002;347:395–400.
   PubMed Web of Science ®Google Scholar
• Childers MK, Brashear A, Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004;85:1063–1069.
   PubMed Web of Science ®Google Scholar
• Rousseaux M, Kozlowski O, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. I Neurol. 2002;249: 76–84.
   PubMed Web of Science ®Google Scholar
• Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. I Neurol Neurosurg Psychiatry. 2000;69:217–221.
   PubMed Web of Science ®Google Scholar
• Kanovsky P, Bares M, Severa S, Richardson A. Long-term efficacy and tolerability of 4-monthly versus yearly botulinum toxin type A treatment for lower-limb spasticity in children with cerebral palsy. Dev Med Child Neurol. 2009;51:436–445.
   PubMed Web of Science ®Google Scholar
• Gordon MF, Brashear A, Elovic E, et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology. 2004;63:1971–1973.
   PubMed Web of Science ®Google Scholar
• Turkel CC, Bowen B, Liu J, Brin MF. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil. 2006;87:786–792.
   PubMed Web of Science ®Google Scholar
• Brashear A, McAfee AL, Kuhn ER, Fyffe J. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil. 2004;85:705–709.
   PubMed Web of Science ®Google Scholar
• Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. I Neurol Neurosurg Psychiatry. 2009;80:380–385.
   PubMed Web of Science ®Google Scholar
• Bender L, McKenna K. Hemiplegic shoulder pain: defining the problem and its management. Disabil Rehabil. 2001;23:698–705.
   PubMed Web of Science ®Google Scholar
• Van Ouwenaller C, Laplace P, Chantraine A. Painful shoulder in hemiplegia. Arch Phys Med Rehabil. 1986;67:23–25.
   PubMed Web of Science ®Google Scholar
• Marco E, Duarte E, Vila J, et al. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. I Rehabil Med. 2007;39:440–447.
   Google Scholar
• Kong KH, Neo JJ, Chua KS. A randomized controlled study of botulinum toxin A in the treatment of hemiplegic shoulder pain associated with spasticity. Clin Rehabil. 2007;21:28–35.
   PubMed Web of Science ®Google Scholar
• Lim JY, Koh JFI, Paik NJ. Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke. 2008;39:126–131.
   PubMed Web of Science ®Google Scholar
• Marciniak C, Harvey R, Gagnon C, et al. A randomized, double-blind placebo-controlled trial of botulinum toxin type A in the treatment of hemiplegic shoulder pain and spasticity [abstract]. Arch Phys Med Rehabil. 2009;1:S100.
   Google Scholar
• Simpson D, Mayer N. Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin. WE MOVE; 2002.
   Google Scholar
• Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 1996;46:1306–1310.
   PubMed Web of Science ®Google Scholar
• Bakheit AM, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke. 2000;31:2402–2406.
   PubMed Web of Science ®Google Scholar
• Shaari CM, Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve. 1993;16:964–969.
   PubMed Web of Science ®Google Scholar
• Deshpande S, Gormley M, Carey J. Muscle fiber orientation in muscles commonly injected with botulinum toxin: an anatomical pilot study. Neurotox Res. 2006;9:115–120.
   PubMed Web of Science ®Google Scholar
• Francisco GE, Boake C, Vaughn A. Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am I Phys Med Rehabil. 2002;81:355–363.
   PubMed Web of Science ®Google Scholar
• Mayer NH, Whyte J, Wannstedt G, Ellis CA. Comparative impact of 2 botulinum toxin injection techniques for elbow flexor hypertonia. Arch Phys Med Rehabil. 2008;89(5): 982–987.
   PubMed Web of Science ®Google Scholar
• Gracies JM, Lugassy M, Weisz DJ, Vecchio M, Flanagan S, Simpson DM. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil. 2009;90:9-16 e2.
   PubMedGoogle Scholar
• Ada L, O'Dwyer N, O'Neill E. Relation between spasticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: an observational study. Disabil Rehabil. 2006;28:891–897.
   PubMed Web of Science ®Google Scholar
• Duncan P, Studenski S, Richards L, et al. Randomized clinical trial of therapeutic exercise in subacute stroke. Stroke. 2003;34:2173–2180.
   PubMed Web of Science ®Google Scholar
• Wolf SL, Winstein CJ, Miller JP, et al. Retention of upper limb function in stroke survivors who have received constraint-induced movement therapy: the EXCITE randomised trial. Lancet Neurol. 2008;7:33–40.
   PubMed Web of Science ®Google Scholar
• Chae J, Hart R. Comparison of discomfort associated with surface and percutaneous intramuscular electrical stimulation for persons with chronic hemiplegia. Am I Phys Med Rehabil. 1998;77:516–522.
   PubMed Web of Science ®Google Scholar
• Levine P, Page SJ. Modified constraint-induced therapy: a promising restorative outpatient therapy. Top Stroke Rehabil. 2004;11:1–10.
   PubMedGoogle Scholar
• Page SJ, Sisto S, Levine P, McGrath RE. Efficacy of modified constraint-induced movement therapy in chronic stroke: a single-blinded randomized controlled trial. Arch Phys Med Rehabil. 2004;85:14–18.
   PubMed Web of Science ®Google Scholar
• Hesse S, Mehrholz J, Werner C. Robot-assisted upper and lower limb rehabilitation after stroke: walking and arm/hand function. Dtsch Arztebl Int. 2008;105:330–336.
   PubMed Web of Science ®Google Scholar
• Levy CE, Giuffrida C, Richards L, Wu S, Davis S, Nadeau SE. Botulinum toxin a, evidence-based exercise therapy, and constraint-induced movement therapy for upper-limb hemiparesis attributable to stroke: a preliminary study. Am I Phys Med Rehabil. 2007;86:696–706.
   PubMed Web of Science ®Google Scholar
• Esquenazi A, Mayer N. Electrical stimulation to prolong the duration of botulinum toxin type A effects on spasticity [abstract]. Arch Phys Med Rehabil. 2007;88:E105.
   PubMedGoogle Scholar
• Hesse S, Reiter F, Konrad M, Jahnke MT. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin Rehabil. 1998;12:381–388.
   PubMed Web of Science ®Google Scholar
• Sun SF, Hsu CW, Sun HP, Hwang CW, Yang CL, Wang JL. Combined botulinum toxin type a with modified constraint-induced movement therapy for chronic stroke patients with upper extremity spasticity: a randomized controlled study. Neurorehabil Neural Repair. 2010;24:34–41.
   PubMed Web of Science ®Google Scholar
• Meythaler JM, Vogtle L, Brunner RC. A preliminary assessment of the benefits of the addition of botulinum toxin A to a conventional therapy program on the function of people with longstanding stroke. Arch Phys Med Rehabil. 2009;90:1453–1461.
   PubMed Web of Science ®Google Scholar